Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 1
2005 1
2006 2
2007 7
2008 7
2009 7
2010 5
2011 4
2012 1
2013 3
2014 3
2015 5
2016 3
2017 2
2018 3
2019 3
2021 5
2022 5
2023 3
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation.
Gassner T, Chittilappilly C, Pirich T, Neuditschko B, Hackner K, Lind J, Aksoy O, Graichen U, Klee S, Herzog F, Wiesner C, Errhalt P, Pecherstorfer M, Podar K, Vallet S. Gassner T, et al. Among authors: vallet s. J Immunother Cancer. 2024 May 3;12(5):e008669. doi: 10.1136/jitc-2023-008669. J Immunother Cancer. 2024. PMID: 38702145
Correction: Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.
Bashari MH, Fan F, Vallet S, Sattler M, Arn M, Luckner-Minden C, Schulze-Bergkamen H, Zörnig I, Marme F, Schneeweiss A, Cardone MH, Opferman JT, Jäger D, Podar K. Bashari MH, et al. Among authors: vallet s. Breast Cancer Res. 2024 Apr 2;26(1):58. doi: 10.1186/s13058-024-01811-y. Breast Cancer Res. 2024. PMID: 38566222 Free PMC article. No abstract available.
Editor's Note: Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment.
Huston A, Leleu X, Jia X, Moreau AS, Ngo HT, Runnels J, Anderson J, Alsayed Y, Roccaro A, Vallet S, Hatjiharissi E, Tai YT, Sportelli P, Munshi N, Richardson P, Hideshima T, Roodman DG, Anderson KC, Ghobrial IM. Huston A, et al. Among authors: vallet s. Clin Cancer Res. 2024 Feb 16;30(4):922. doi: 10.1158/1078-0432.CCR-24-0181. Clin Cancer Res. 2024. PMID: 38362725 No abstract available.
Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study.
Kafka M, Giannini G, Artamonova N, Neuwirt H, Ofner H, Kramer G, Bauernhofer T, Luger F, Höfner T, Loidl W, Griessner H, Lusuardi L, Bergmaier A, Berger A, Winder T, Weiss S, Bauinger S, Krause S, Drerup M, Heinrich E, Schneider M, Madersbacher S, Vallet S, Stoiber F, Laimer S, Hruby S, Schachtner G, Nagele U, Lenart S, Ponholzer A, Pfuner J, Wiesinger C, Kamhuber C, Müldür E, Bektic J, Horninger W, Heidegger I. Kafka M, et al. Among authors: vallet s. Clin Genitourin Cancer. 2024 Apr;22(2):458-466.e1. doi: 10.1016/j.clgc.2023.12.018. Epub 2024 Jan 4. Clin Genitourin Cancer. 2024. PMID: 38267304 Free article.
Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT.
Pleyer L, Vaisband M, Drost M, Pfeilstöcker M, Stauder R, Heibl S, Sill H, Girschikofsky M, Stampfl-Mattersberger M, Pichler A, Hartmann B, Petzer A, Schreder M, Schmitt CA, Vallet S, Melchardt T, Zebisch A, Pichler P, Zaborsky N, Machherndl-Spandl S, Wolf D, Keil F, Hasenauer J, Larcher-Senn J, Greil R. Pleyer L, et al. Among authors: vallet s. Am J Hematol. 2023 Nov;98(11):1685-1698. doi: 10.1002/ajh.27046. Epub 2023 Aug 7. Am J Hematol. 2023. PMID: 37548390
Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMT.
Pleyer L, Heibl S, Tinchon C, Vallet S, Schreder M, Melchardt T, Stute N, Föhrenbach Quiroz KT, Leisch M, Egle A, Scagnetti L, Wolf D, Beswick R, Drost M, Larcher-Senn J, Grochtdreis T, Vaisband M, Hasenauer J, Zaborsky N, Greil R, Stauder R. Pleyer L, et al. Among authors: vallet s. Cancers (Basel). 2023 Feb 22;15(5):1388. doi: 10.3390/cancers15051388. Cancers (Basel). 2023. PMID: 36900181 Free PMC article.
The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy.
D'Andrea D, Shariat SF, Soria F, Mari A, Mertens LS, Di Trapani E, Carrion DM, Pradere B, Pichler R, Filippot R, Grisay G, Del Giudice F, Laukhtina E, Paulnsteiner D, Krajewski W, Vallet S, Maggi M, De Berardinis E, Álvarez-Maestro M, Brönimann S, Di Maida F, van Rhijn BWG, Hendricksen K, Moschini M; European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group. D'Andrea D, et al. Among authors: vallet s. Eur Urol Open Sci. 2022 May 28;41:74-80. doi: 10.1016/j.euros.2022.05.001. eCollection 2022 Jul. Eur Urol Open Sci. 2022. PMID: 35813257 Free PMC article.
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group.
Leisch M, Pfeilstöcker M, Stauder R, Heibl S, Sill H, Girschikofsky M, Stampfl-Mattersberger M, Tinchon C, Hartmann B, Petzer A, Schreder M, Kiesl D, Vallet S, Egle A, Melchardt T, Piringer G, Zebisch A, Machherndl-Spandl S, Wolf D, Keil F, Drost M, Greil R, Pleyer L. Leisch M, et al. Among authors: vallet s. Cancers (Basel). 2022 May 17;14(10):2459. doi: 10.3390/cancers14102459. Cancers (Basel). 2022. PMID: 35626063 Free PMC article.
69 results